speaker
Tina
Conference Operator

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Farmer Mac third quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. To ask a question, press star, then one on your touchtone phone. It is now my pleasure to turn the call over to Eric Etsy, Director of Capital Markets. Please go ahead.

speaker
Eric Esty
Director of Capital Markets

Good afternoon and thank you for joining us for our third quarter 2026 earnings conference call. I'm Eric Esty, Director of Capital Markets here at Farmer Mac. As we begin, please note that the information provided during this call may contain forward-looking statements about the company's business, strategies, and prospects. These statements are based on management's current expectations and assumptions and are subject to risks and uncertainties that could cause our actual results to differ materially from those projected. All forward-looking statements are based on information available to FARMAC as of today's date, and FARMAC assumes no obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, except as required by applicable law. Please refer to PharmaMac's 2025 Annual Report on Form 10-K and subsequent SEC filings for a full discussion of the company's risk factors. On today's call, we will also be discussing certain non-GAAP financial measures. Disclosures and reconciliations of these non-GAAP measures can be found in the company's most recent earnings press release posted on PharmaMac's website. Joining me today are our President and Chief Executive Officer, Zach Carpenter, and our Executive Vice President and Chief Financial Officer, Matt Pullins. At this time, I'll turn the call over to our Chief Executive Officer, Zach Carpenter. Zach?

speaker
Zach Carpenter
President and Chief Executive Officer

Thank you, Eric, and good afternoon, everyone. Thank you for joining us today. I'm pleased to report that PharmaMac delivered another extremely strong quarter. Total business volume achieved another record, reaching $38.5 billion as of the end of the third quarter of 2026. In addition, our third quarter financial results were record performance for the first nine months of 2026 with $357.9 million in revenues and $163.1 million in core earnings, which is an increase of 18.3% and 14.1% respectively from the same period of 2025. These record results were powered by broad-based business volume growth and reflect the strengths of our mission-driven franchise, diversified business segments, and the disciplined execution of our strategy across every part of the business. Notably, this performance was achieved against the backdrop of an increasingly dynamic, uncertain, and in many cases, more challenging environment. PharmaMac's ability to successfully navigate these cross-currents is a testament to our team and the strength of our market position. FarmerMac continues to be a critical part of the financial ecosystem through providing liquidity in support of agriculture and rural infrastructure. As we execute our strategy, which we outlined at our 2026 Investor Day, we are on track to achieve $40 billion in business volume this year, reaching a key milestone two years ahead of the timeline outlined during our 2026 Investor Day. We continue to expect business volume growth to average approximately 8% to 11% annually through 2030, reflecting balanced expansion across our mission-focused businesses. Our strong performance to date has us tracking ahead of the pace required to achieve our 2030 guidance and positions us favorably relative to our previously communicated targets. While business volume growth remains an important measure of mission fulfillment and a key strategic priority, our ultimate objective is to generate sustainable earnings growth that strengthens our ability to support rural America and deliver long-term value for our stakeholders. Accordingly, we remain focused on expense management, achieving operating leverage while making targeted investments to support efficient execution. This quarter, we continue to execute on those priorities, delivering strong growth, maintaining an efficiency ratio below 30% target and providing 2.7 billion of liquidity to critical sectors of the American economy. Outstanding business volume increased $1.3 billion in the third quarter of 2026 after taking into account all new business volume as well as maturity, sales, and pay downs on existing assets. This third quarter business volume increase was powered by broad-based growth led by our infrastructure finance line of business, where net outstanding business volume grew $920 million. This was driven by record quarterly net business volume growth in our renewable energy segment, were loan purchases and unfunded commitments grew 19.5% sequentially and contributed to over 45% of the increase in total net outstanding business volume in the quarter. We continue to see strong opportunities across our entire infrastructure finance portfolio, driven by a once in a generation investment in data center infrastructure, cloud storage and enterprise digitization, as well as increased onshore manufacturing leading to significant energy generation capacity demand in addition to ongoing grid monetization and upgrades. The scale and velocity of capital needed to support these demands are driving infrastructure growth tailwinds. We see comparable tailwinds in agricultural finance as financial institutions adapt to changing market conditions, balance sheet priorities, and risk management objectives leading to a shifting competitive landscape. We believe these evolving dynamics reinforce the value of PharmaMax's role in serving as a secondary market to rural America and position us for continued growth. Turning to our agricultural finance line of business, loan purchase activity in our farm and ranch segment had a strong quarter in what is typically a seasonally slower quarter for volume growth, sustaining the elevated pace that began in the fourth quarter of 2025 and continued through the first three quarters of 2026. This growth was aided by the first full quarter of Farmer Mac Loan Exchange, or FLEX, which makes it significantly easier for originators to submit loans to our ecosystem. We approved almost $700 million in loans during the third quarter of 2026, a record in loan approvals for any third quarter in our history. We saw net growth in loan purchases of $228 million during the quarter. outpacing the seasonally large number of loan repayments we typically see in the third quarter due to the July 1st payment date. We continue to operate at an elevated pace for new business volume and expect loan purchase growth to continue as lenders seek liquidity driven by the need to diversify from high-cost deposits amid strong loan growth, a focus on a capital efficiency and returns, and ongoing volatility that many sectors of the agricultural economy are experiencing. This quarter's growth in Farm and Ranch also benefited from an acquisition of field servicing rights associated with $1.4 billion of loans completed in July. The Corporate Act finance segment grew modestly again this quarter to $2.14 billion in outstanding business volume. While deal flow activity in the broader agribusiness market was relatively muted during the first nine months of 2026, we have seen a sizable pickup in transactions heading into the fourth quarter of 2026. Two key themes have emerged driving this increase. First, transaction sizes are getting larger as agribusinesses look to enhance scale and navigate macro volatility, requiring incremental liquidity. Second, financial institutions continue to elevate, evaluate concentration levels and return on capital dynamics within the broader agribusiness sectors. In certain instances, this evaluation has resulted in decisions to reduce exposure or exit transactions entirely. The combination of these factors results in the need for incremental liquidity to support critical agribusinesses, and more financial institutions are turning to FarmerMac for reliable and consistent liquidity needed to support their borrowers. Turning to our infrastructure finance line of business, outstanding business volume increased $920 million sequentially to over $14 billion as of quarter end, with all three segments contributing to net growth. This is a continuation of similar themes we have seen over the last year. Specifically, the strong interest and investment in data center construction, broadband expansion, and the construction and completion of renewable energy projects, reflecting the overall need for significant energy generation and transmission capacity in rural America. Net business volume growth in our power and utility segment this quarter was $165 million. driven by strong net loan purchases of $208 million or an increase of 5.2% from the prior quarter. Excluding the $197 million full purchase in the second quarter of 2026, net growth in power and utilities loan purchases accelerated to over 70% compared to net growth last quarter. We continue to see a steady demand for capital in this segment as borrowers invest in system upgrades and grid modernization to support the significant increase in electrification demand, as well as lenders managing their balance sheets. During the quarter, we provided over $1 billion in gross renewable energy loan purchases and unfunded commitments, and after scheduled maturities and repayments grew $586 million. This was the largest quarterly growth in net business volume in our history for this segment, surpassing the prior record by over $140 million. We expect a substantial need for new power generation to continue to drive renewable energy project demand, more than offsetting the natural runoff from a maturing portfolio. Current deal flow remains robust, with our pipeline approaching $1 billion, underscoring the strength of our reputation and role in the market and allowing us to selectively deploy capital focused on appropriate returns and structures with strong counterparties. While the industry continues to adjust to the HR1 phase-out of tax credits beyond 2027, as well as supply chain dynamics, we expect increased demand for energy generation to position the industry for continued growth. Even excluding tax incentives, the underlying economics of these renewable energy projects remain highly competitive, particularly with speed to market, as renewable energy project development timelines are often shorter compared to traditional power sources. Broadband infrastructure also posted another strong quarter with net growth of $169 million, ending the period at just over $2 billion in business volume. While data center project investments continue to see strong demand, we have also focused on diversified business volume growth, providing liquidity to appropriately structured transactions supporting fiber, broadband, and tower projects that enhance critical digital infrastructure for rural communities. While the segment's growth has been substantial, our approach remains grounded in a close reading of market dynamics, and that discipline informs every decision we make. As the portfolio matures, we have intensified our portfolio management efforts, deliberately diversifying by geography, subsegment, sponsor, and tenant, and pursuing a mix of funded financing structures so that the portfolio remains diversified and resilient should market contingents become less favorable. Through the first nine months of 2026, we generated $10.5 billion in gross business volume supporting lenders and borrowers across rural America, exceeding the gross business volume generated in any annual period in PharmaMax history. That number best captures our mission in action, broadening access to competitive financing for American agriculture and rural communities. Backed by our robust pipeline across all segments and a strong capital position, We enter the final quarter of this year and look to 2027 with the disciplined execution that produces durable, high-quality earnings and a runway to continue to growing. We continue to remain mindful of the macroeconomic backdrop, including uncertainty around interest rates, trade and government policy, regulatory change, and geopolitical dynamics. A diversified portfolio that supports critical sectors of the U.S. economy strong capital and liquidity position, disciplined underwriting, and a focus on expense management all taken together give us great confidence that we can keep delivering consistent and durable results. However these backdrop dynamics play out, we believe PharmaMac is uniquely well positioned to navigate the environment and continue to deliver on our mission. With that, I'd like to turn it over to Matt Pullins, our Executive Vice President and Chief Financial Officer to review our financial results in more detail. Matt.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API